SRC-3 gene deletion leads to long-lasting anti-cancer response.
Eliminating the gene SRC-3 in regulatory T cells (Tregs) triggers a lifelong anti-cancer response that eradicates tumors without negative side effects, according to a study by researchers at Baylor College of Medicine. The study shows that Tregs lacking SRC-3 proliferate extensively and infiltrate tumors, releasing compounds that generate an anti-tumor immune response. The modified Tregs block other immune cells that attempt to stop the anti-tumor response. The findings encourage further investigations to determine the value of this approach to treat human cancer.